David. R. Sherman

David. R. Sherman

Auto-generated profile, based on publicly available information

David. R. Sherman

Department of Microbiology, University of Washington

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ALArianne Lovey
Arianne Lovey
SVSheetal Verma
Sheetal Verma
VKVaishnavi Kaipilyawar
Vaishnavi Kaipilyawar
RRRodrigo Ribeiro-Rodrigues
Rodrigo Ribeiro-Rodrigues
SHSeema Husain
Seema Husain
PSPadmini Salgame
Padmini Salgame
Mechanisms underlying variability in transmission of Mycobacterium tuberculosis strains remain undefined. By characterizing high and low transmission strains of M.tuberculosis in mice, we show here that high transmission M.tuberculosis strain induce rapid IL-1R-dependent alveolar macrophage migration from the alveolar space into the interstitium and that this action is key to subsequent temporal events of early dissemination of bacteria to the lymph nodes, Th1 priming, granulomatous response and bacterial control. In contrast, IL-1R-dependent alveolar macrophage migration and early dissemination of bacteria to lymph nodes is significantly impeded in infection with low transmission M.tuberculosis strain; these events promote the development of Th17 immunity, fostering neutrophilic inflammation and increased bacterial replication. Our results suggest that by inducing granulomas with the potential to develop into cavitary lesions that aids bacterial escape into the airways, high transmission M.tuberculosis strain is poised for greater transmissibility. These findings implicate bacterial heterogeneity as an important modifier of TB disease manifestations and transmission.

24 December 2019 in mBio
Verified
Journal Article
Open access
PDF file
Shuyi MaShuyi Ma
Shuyi Ma
SJSuraj Jaipalli
Suraj Jaipalli
JLJonah Larkins-Ford
Jonah Larkins-Ford
JLJenny Lohmiller
Jenny Lohmiller
BABree B Aldridge
Bree B Aldridge
SCSriram Chandrasekaran
Sriram Chandrasekaran
Multidrug combination therapy is an important strategy for treating tuberculosis, the world’s deadliest bacterial infection. Long treatment durations and growing rates of drug resistance have created an urgent need for new approaches to prioritize effective drug regimens. Hence, we developed a computational model called INDIGO-MTB that identifies synergistic drug regimens from an immense set of possible drug combinations using the pathogen response transcriptome elicited by individual drugs. Although the underlying input data for INDIGO-MTB was generated under in vitro broth culture conditions, the predictions from INDIGO-MTB correlated significantly with in vivo drug regimen efficacy from clinical trials. INDIGO-MTB also identified the transcription factor Rv1353c as a regulator of multiple drug interaction outcomes, which could be targeted for rationally enhancing drug synergy.

5 October 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
RJRichard M. Jones
Richard M. Jones
KAKristin N. Adams
Kristin N. Adams
HEHassan E. Eldesouky
Hassan E. Eldesouky
DSDavid R. Sherman
David R. Sherman
Tuberculosis, caused by Mycobacterium tuberculosis (Mtb) is an ancient disease that has remained a leading cause of infectious death. Mtb has evolved drug resistance to every antibiotic regimen ever introduced, greatly complicating treatment, lowering rates of cure and menacing TB control in parts of the world. As technology has advanced, our understanding of antimicrobial resistance has improved, and our models of the phenomenon have evolved. In this review, we focus on recent research progress that supports an updated model for the evolution of drug resistance in Mtb. We highlight the contribution of drug tolerance on the path to resistance, and the influence of heterogeneity on tolerance. Resistance is likely to remain an issue for as long as drugs are needed to treat TB. However, with technology driving new insights and careful management of newly developed resources, antimicrobial resistance need not continue to threaten global progress against TB, as it has done for decades.

23 November 2020 in Annual Review of Genetics
Verified
Journal Article
Closed access
JPJulian S. Peters
Julian S. Peters
NINabila Ismail
Nabila Ismail
DADippenaar Anzaan
Dippenaar Anzaan
Shuyi MaShuyi Ma
Shuyi Ma
DSDavid R. Sherman
David R. Sherman
BKBavesh Kana
Bavesh Kana
Tuberculosis claims more human lives than any other bacterial infectious disease and represents a clear and present danger to global health as new tools for vaccination, treatment, and interruption of transmission have been slow to emerge. Additionally, tuberculosis presents with notable clinical heterogeneity, which complicates diagnosis, treatment, and the establishment of nonrelapsing cure. How this heterogeneity is driven by the diversity ofclinical isolates of the causative agent, Mycobacterium tuberculosis, has recently garnered attention. Herein, we review advances in the understanding of how naturally occurring variation in clinical isolates affects transmissibility, pathogenesis, immune modulation, and drug resistance. We also summarize how specific changes in transcriptional responses can modulate infection or disease outcome, together with strain-specific effects on gene essentiality. Further understanding of how this diversity of M. tuberculosis isolates affects disease and treatment outcomes will enable the development of more effective therapeutic options and vaccines for this dreaded disease.

23 January 2023 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
AFAndrew Frando
Andrew Frando
VBVishant Boradia
Vishant Boradia
MGMarina A Gritsenko
Marina A Gritsenko
CBClaude Beltejar
Claude Beltejar
LDLe Day
Le Day
CGChristoph Grundner
Christoph Grundner

16 November 2020 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
Shuyi MaShuyi Ma
Shuyi Ma
RMRobert Morrison
Robert Morrison
SHSamuel J. Hobbs
Samuel J. Hobbs
Vijay SoniVijay Soni
Vijay Soni
JFJessica Farrow-Johnson
Jessica Farrow-Johnson
DSDavid R. Sherman
David R. Sherman